New strategies to develop new medications for lung cancer and metastasis

Yujie Zhao, Alex Adjei

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

With the advances in cancer and molecular biology and the rapid progress in genomics, significant progress has been made in the treatment of lung cancer in the past decade. Targeted therapies have been developed for nonsmall cell lung cancer (NSCLC), and significant improvement in survival has been achieved. There is still, however, no cure for advanced NSCLC. Resistance to initial therapy is universal, and the lethal outcome of metastatic disease still remains. Approaches to preventing metastases and overcoming resistance to therapy are necessary to ensure long-term survival of patients with advanced lung cancer.

Original languageEnglish (US)
Pages (from-to)265-275
Number of pages11
JournalCancer and Metastasis Reviews
Volume34
Issue number2
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

    Fingerprint

Keywords

  • ALK
  • CTLA-1
  • EGFR
  • Immunotherapy
  • Lung cancer
  • NSCLC
  • PD-1
  • PD-L1
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this